Hommam Al Nassim 
The director of the Russian “Gamaleya” Center for Microbiology, Alexander Gintsburg, announced the development of a new cancer treatment vaccine that will be allocated to each patient individually using artificial intelligence.
Gintsburg stated that an integrated laboratory has been equipped to design software based on high-level Russian artificial intelligence, which contributes to determining the appropriate composition of the vaccine based on a detailed analysis of data related to tumors for each case.
He also explained that the expected program is currently developing an innovative approach that allows tumor analysis and the preparation of an effective vaccine plan in less than a week, indicating that this technology is revolutionary in the field of personalized cancer treatment, as it responds to the individual variables of each patient, which enhances the effectiveness of treatment.
Ginsburg had announced that clinical trials of the vaccine are scheduled to begin in mid-2025. He also pointed to promising results from pre-clinical experiments conducted on mice with melanoma, where the vaccine was able to significantly reduce the size of tumors within 15 days of vaccination. While the mice that did not receive the vaccine died between days 19 and 22.
For his part, Russian Health Minister Mikhail Murashko confirmed that the results of preliminary studies of the vaccine are expected to be published by the end of this year, noting the importance of this step in progressing towards an effective personalized treatment for cancer.
The Russian Defense Minister announces the liberation of 28 new towns in May